Phillipp Hartmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8932533/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. Hepatology, 2022, 75, 219-228.	7.3	107
2	Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice. Hepatology International, 2022, 16, 359-370.	4.2	15
3	The fecal mycobiome in non-alcoholic fatty liver disease. Journal of Hepatology, 2022, 76, 788-799.	3.7	66
4	Intestinal virome in patients with alcohol use disorder and after abstinence. Hepatology Communications, 2022, 6, 2058-2069.	4.3	18
5	Editorial: The Microbiome in Hepatobiliary and Intestinal Disease. Frontiers in Physiology, 2022, 13, 893074.	2.8	6
6	Liver cirrhosis and immune dysfunction. International Immunology, 2022, 34, 455-466.	4.0	12
7	New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease, 2021, 41, 087-102.	3.6	10
8	Dynamic Changes of the Fungal Microbiome in Alcohol Use Disorder. Frontiers in Physiology, 2021, 12, 699253.	2.8	45
9	Gut microbiota in liver disease: too much is harmful, nothing at all is not helpful either. American Journal of Physiology - Renal Physiology, 2019, 316, G563-G573.	3.4	54
10	Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. Journal of Hepatology, 2018, 69, 396-405.	3.7	144
11	Risk factors for progression of and treatment options for NAFLD in children. Clinical Liver Disease, 2018, 11, 11-15.	2.1	19
12	Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. Hepatology, 2018, 67, 2150-2166.	7.3	189
13	Reply to: "Finding fibroblast growth factor 19 during cholestasis: Does x mark the spot?. Journal of Hepatology, 2018, 69, 1400-1401.	3.7	0
14	Intestinal fungi contribute to development of alcoholic liver disease. Journal of Clinical Investigation, 2017, 127, 2829-2841.	8.2	336
15	Deficiency of intestinal mucin-2 protects mice from diet-induced fatty liver disease and obesity. American Journal of Physiology - Renal Physiology, 2016, 310, G310-G322.	3.4	38
16	Intestinal REG3 Lectins Protect against Alcoholic Steatohepatitis by Reducing Mucosa-Associated Microbiota and Preventing Bacterial Translocation. Cell Host and Microbe, 2016, 19, 227-239.	11.0	284
17	Tiny RNA with great effects: miR-155 in alcoholic liver disease. Journal of Hepatology, 2016, 64, 1214-1216.	3.7	28
18	Methods to determine intestinal permeability and bacterial translocation during liver disease. Journal of Immunological Methods, 2015, 421, 44-53.	1.4	199

PHILLIPP HARTMANN

#	Article	IF	CITATIONS
19	Alcoholic Liver Disease: The Gut Microbiome and Liver Cross Talk. Alcoholism: Clinical and Experimental Research, 2015, 39, 763-775.	2.4	226
20	Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids. Journal of Hepatology, 2014, 60, 1259-1267.	3.7	28
21	Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. Hepatology, 2013, 58, 108-119.	7.3	187
22	The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease. Frontiers in Physiology, 2012, 3, 402.	2.8	86
23	928 Deficiency of Intestinal Mucin-2 Protects From Alcoholic Liver Disease in Mice. Gastroenterology, 2012, 142, S-935.	1.3	0
24	Toll-Like Receptor 2–Mediated Intestinal Injury and Enteric Tumor Necrosis Factor Receptor I Contribute to Liver Fibrosis in Mice. Gastroenterology, 2012, 143, 1330-1340.e1.	1.3	108